Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) was upgraded by stock analysts at Baird R W to a “strong-buy” rating in a report issued on Tuesday, Zacks.com reports.
Other equities analysts also recently issued reports about the company. Royal Bank of Canada lifted their target price on Contineum Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Wednesday, August 14th. Robert W. Baird assumed coverage on shares of Contineum Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $32.00 target price on the stock. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $29.50.
Check Out Our Latest Report on CTNM
Contineum Therapeutics Stock Performance
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02). On average, research analysts forecast that Contineum Therapeutics will post -2.04 earnings per share for the current year.
Institutional Trading of Contineum Therapeutics
A number of large investors have recently made changes to their positions in the company. Sandia Investment Management LP purchased a new position in Contineum Therapeutics in the second quarter worth approximately $88,000. Rhumbline Advisers acquired a new stake in shares of Contineum Therapeutics in the 2nd quarter valued at $118,000. Bank of New York Mellon Corp purchased a new stake in shares of Contineum Therapeutics during the 2nd quarter worth $356,000. Driehaus Capital Management LLC acquired a new position in shares of Contineum Therapeutics during the second quarter worth $1,174,000. Finally, Squarepoint Ops LLC purchased a new position in Contineum Therapeutics in the second quarter valued at $2,642,000.
Contineum Therapeutics Company Profile
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Featured Stories
- Five stocks we like better than Contineum Therapeutics
- Using the MarketBeat Stock Split Calculator
- Bet on These 3 High-Yield Stocks as Natural Gas Demand Grows
- P/E Ratio Calculation: How to Assess Stocks
- Gold Prices Hit Record Highs: Is It Time to Buy or Take Profits?
- Pros And Cons Of Monthly Dividend Stocks
- Value Stocks Gaining Momentum – Will They Beat Growth Stocks?
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.